KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ugi (UGI) Asset Writedowns and Impairment (2016 - 2025)

Ugi's Asset Writedowns and Impairment history spans 17 years, with the latest figure at $13.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 8.33% year-over-year to $13.0 million, compared with a TTM value of $38.0 million through Dec 2025, down 73.43%, and an annual FY2025 reading of $37.0 million, down 39.34% over the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $13.0 million at Ugi, down from $37.0 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $62.0 million in Q2 2024, with the low at -$41.0 million in Q3 2022.
  • Average Asset Writedowns and Impairment over 5 years is $16.4 million, with a median of $16.0 million recorded in 2023.
  • Biggest YoY gain for Asset Writedowns and Impairment was 200.0% in 2022; the steepest drop was 472.73% in 2022.
  • Tracing UGI's Asset Writedowns and Impairment over 5 years: stood at $11.0 million in 2021, then rose by 18.18% to $13.0 million in 2022, then grew by 23.08% to $16.0 million in 2023, then fell by 25.0% to $12.0 million in 2024, then increased by 8.33% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for UGI's Asset Writedowns and Impairment are $13.0 million (Q4 2025), $37.0 million (Q3 2025), and -$33.0 million (Q2 2025).